Although we know that the level of soluble Aβo begin to increase in the brain ~10–15 years before any clinical symptoms of AD (Cline et al., 2018), it still need to be established if the hyperactivity observed in early AD patients is induced, at least partly, by this progressive accumulation of soluble Aβo in the brain as shown in vitro and in animal models. The gene discussed is ABO; the disease is Alzheimer disease.